Vaccines

Pfizer and BioNTech claim their two-dose COVID-19 mRNA vaccine (BNT162b2) is more than 90 percent effective.

We ask medicine makers around the world to tell us how their professional and personal lives have changed over the course of the COVID-19 crisis.

When following COVID-19 research, it’s hard to keep your eye on the ball...

A vaccine must be able to reach patients who need it. Reliable partners and procedures are a must.

Global access to the vaccine is essential to provide protection against the virus. A big hurdle to accessibility will likely be price.

Most clinical trials against COVID-19 exclude the very patients most at risk from the disease.

A typical vaccine takes around 10 to 12 years to reach the market. A key question: “Where should we base production?”

Nominations are now open for The Medicine Maker 2021 Power List.

GlaxoSmithKline has launched a vaccine awareness campaign in the USA as immunization rates drop amidst the pandemic.

Virus-based vaccines were the first foray into immunization, but the field has had to move on and embrace new approaches.